Diagnosis and Treatment of HER2-Positive Breast Cancer
10.3904/kjm.2025.100.2.81
- Author:
Suee LEE
1
Author Information
1. Division of Hematology and Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
- Publication Type:20
- From:Korean Journal of Medicine
2025;100(2):81-85
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Human epidermal growth factor receptor-2 (HER2)-positive breast cancer accounts for approximately 20% of all breast cancer cases. The advent of therapies targeting HER2 has significantly improved the prognosis for HER2-positive breast cancer. Neoadjuvant/adjuvant chemotherapy with HER2-targeted agents is recommended for early and locally advanced breast cancer. The appropriate use of novel HER2-targeted therapies is recommended for metastatic breast. We aimed to examine the diagnosis and personalized treatment for HER2-positive breast cancer.
